Recent Updates
Recently added Catalysts
DTIL Positive Sentiment

Precision BioSciences Strengthens Senior Leadership Team Ahead of Anticipated PBGENE-HBV Clinical Execution

Thursday, September 12, 2024 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Precision BioSciences has announced key leadership changes, appointing Murray Abramson as Senior Vice President and Head of Clinical Development, and John Fry as Strategic Clinical Advisor for Hepatitis. Additionally, Alan List will retire as Chief Medical Officer but will continue as a Clinical Consultant on the Scientific Advisory Board. These changes aim to bolster the company's clinical execution for PBGENE-HBV.
Price reaction · baseline $10.5 (2024-09-11 close) · hit pre-market · clean, no other DTIL news in the window
day 0 close
-0.1%

Market Sentiment Analysis

POSITIVE FACTORS

  • Appointment of experienced leaders to strengthen the team.
  • Murray Abramson brings valuable expertise in clinical development.
  • Strategic clinical advisor role enhances focus on Hepatitis.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+24%
120-day peak, hindsight
Typical move
4.8%
average across 2 past catalysts
Cash runway
~19 mo
Low dilution risk
Lead asset
Targeted CEA CAR-T
Phase 1 · Advanced Lung Cancer

Full Press Release Details

– Murray Abramson , MD, MPH appointed as Senior Vice President, Head of Clinical Development- – John Fry appointed as Strategic Clinical Advisor, Hepatitis – – Alan List , MD, Chief Medical Officer to Retire and Assume Role as Clinical Consultant as part of Precision’s Scientific Advisory Board –

Frequently Asked Questions

Who was appointed as Senior Vice President?

Murray Abramson, MD, MPH was appointed as Senior Vice President.

What role will John Fry serve at Precision BioSciences?

John Fry has been appointed as Strategic Clinical Advisor for Hepatitis.

What will happen to Alan List's position?

Alan List will retire as Chief Medical Officer and become a Clinical Consultant.

What is the focus of the leadership changes?

The changes aim to strengthen clinical execution for PBGENE-HBV.

ShareAdd on Google
Tags: DTIL Viatris Investor Conferences Healthcare Murray Abramson John Fry Alan List PBGENE-HBV
Last updated: Sep 12, 2024

Biotech snapshot

Cash runway
$88M liquidity · $4M/mo burn
~19 mo
Low dilution risk
Lead asset
Targeted CEA CAR-TPhase 1
Advanced Lung Cancer →

Catalyst track record

+24%
best trade around DTIL's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for DTIL.

See every catalyst's timing & PoA →